REFERENCES
1. Saletta F, Dalla Pozza L, Byrne JA. Genetic causes of cancer predisposition in children and adolescents. Transl Pediatr , 2015 4: 67–75.
2. Downing JR, Wilson RK, Zhang J, Mardis ER, Pui C-H, Ding L, Ley TJ, Evans WE. The Pediatric Cancer Genome Project. Nat Genet , 2012 44: 619–622.
3. Zhang J, Walsh MF, Wu G, Edmonson MN, Gruber TA, Easton J, Hedges D, Ma X, Zhou X, Yergeau DA, Wilkinson MR, Vadodaria B, Chen X, McGee RB, Hines-Dowell S, Nuccio R, Quinn E, Shurtleff SA, Rusch M, Patel A, Becksfort JB, Wang S, Weaver MS, Ding L, Mardis ER, Wilson RK, Gajjar A, Ellison DW, Pappo AS, Pui C-H, Nichols KE, Downing JR. Germline Mutations in Predisposition Genes in Pediatric Cancer. N Engl J Med , 2015 373: 2336–2346.
4. Kindler O, Quehenberger F, Benesch M, Seidel MG. The Iceberg Map of germline mutations in childhood cancer [Internet]. Curr Opin Pediatr , 2018 30: 855–863. [cited 2021 Jan 7] Available from: http://journals.lww.com/00008480-201812000-00023
5. Grobner SN, Worst BC, Weischenfeldt J, Buchhalter I, Kleinheinz K, Rudneva VA, Johann PD, Balasubramanian GP, Segura-Wang M, Brabetz S, Bender S, Hutter B, Sturm D, Pfaff E, Hubschmann D, Zipprich G, Heinold M, Eils J, Lawerenz C, Erkek S, Lambo S, Waszak S, Blattmann C, Borkhardt A, Kuhlen M, Eggert A, Fulda S, Gessler M, Wegert J, Kappler R, Baumhoer D, Burdach S, Kirschner-Schwabe R, Kontny U, Kulozik AE, Lohmann D, Hettmer S, Eckert C, Bielack S, Nathrath M, Niemeyer C, Richter GH, Schulte J, Siebert R, Westermann F, Molenaar JJ, Vassal G, Witt H, Burkhardt B, Kratz CP, Witt O, van Tilburg CM, Kramm CM, Fleischhack G, Dirksen U, Rutkowski S, Fruhwald M, von Hoff K, Wolf S, Klingebiel T, Koscielniak E, Landgraf P, Koster J, Resnick AC, Zhang J, Liu Y, Zhou X, Waanders AJ, Zwijnenburg DA, Raman P, Brors B, Weber UD, Northcott PA, Pajtler KW, Kool M, Piro RM, Korbel JO, Schlesner M, Eils R, Jones DTW, Lichter P, Chavez L, Zapatka M, Pfister SM. The landscape of genomic alterations across childhood cancers. Nature , 2018 555: 321–327.
6. Ma X, Liu Y, Liu Y, Alexandrov LB, Edmonson MN, Gawad C, Zhou X, Li Y, Rusch MC, John E, Huether R, Gonzalez-Pena V, Wilkinson MR, Hermida LC, Davis S, Sioson E, Pounds S, Cao X, Ries RE, Wang Z, Chen X, Dong L, Diskin SJ, Smith MA, Auvi JMG, Meltzer PS, Lau CC, Perlman EJ, Maris JM, Meshinchi S, Hunger SP, Gerhard DS, Zhang J. Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. Nature , 2018.
7. Alejandro Sweet-Cordero E, Biegel JA. The genomic landscape of pediatric cancers: Implications for diagnosis and treatment. Science (80- ) , 2019.
8. Akhavanfard S, Padmanabhan R, Yehia L, Cheng F, Eng C. Comprehensive germline genomic profiles of children, adolescents and young adults with solid tumors [Internet]. Nat Commun 2020 111 , 2020 11: 1–13. [cited 2021 Aug 17] Available from: https://www.nature.com/articles/s41467-020-16067-1
9. Capasso M, Montella A, Tirelli M, Maiorino T, Cantalupo S, Iolascon A. Genetic Predisposition to Solid Pediatric Cancers. Front Oncol , 2020 0: 2083.
10. Newman S, Nakitandwe J, Kesserwan CA, Azzato EM, Wheeler DA, Rusch M, Shurtleff S, Hedges DJ, Hamilton K V, Foy SG, Edmonson MN, Thrasher A, Bahrami A, Orr BA, Klco JM, Gu J, Harrison LW, Wang L, Clay MR, Ouma A, Silkov A, Liu Y, Zhang Z, Liu Y, Brady SW, Zhou X, Chang T-C, Pande M, Davis E, Becksfort J, Patel A, Wilkinson MR, Rahbarinia D, Kubal M, Maciaszek JL, Pastor V, Knight J, Gout AM, Wang J, Gu Z, Mullighan CG, Mcgee RB, Quinn EA, Nuccio R, Mostafavi R, Gerhardt EL, Taylor LM, Valdez JM, Hines-Dowell SJ, Pappo AS, Robinson G, Johnson L-M, Pui C-H, Ellison DW, Downing JR, Zhang J, Nichols KE. Genomes for Kids: The scope of pathogenic mutations in pediatric cancer revealed by comprehensive DNA and RNA sequencing, 2021.
11. Heck JE, Meyers TJ, Lombardi C, Park AS, Cockburn M, Reynolds P, Ritz B. Case-control study of birth characteristics and the risk of hepatoblastoma. Cancer Epidemiol , 2013 37: 390–395.
12. Stiller CA, Pritchard J, Steliarova-Foucher E. Liver cancer in European children: incidence and survival, 1978-1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer , 2006 42: 2115–2123.
13. Czauderna P, Garnier H. Hepatoblastoma: current understanding, recent advances, and controversies. F1000Research , 2018 7: 53.
14. Feng J, Polychronidis G, Heger U, Frongia G, Mehrabi A, Hoffmann K. Incidence trends and survival prediction of hepatoblastoma in children: A population-based study [Internet]. Cancer Commun , 2019 39: 62. [cited 2020 Jun 14] Available from: http://doi.wiley.com/10.1186/s40880-019-0411-7
15. Aguiar TFM, Rivas MP, Costa S, Maschietto M, Rodrigues T, Sobral de Barros J, Barbosa AC, Valieris R, Fernandes GR, Bertola DR, Cypriano M, Caminada de Toledo SR, Major A, Tojal I, Apezzato ML de P, Carraro DM, Rosenberg C, Lima da Costa CM, Cunha IW, Sarabia SF, Terrada D-L, Krepischi ACV. Insights Into the Somatic Mutation Burden of Hepatoblastomas From Brazilian Patients [Internet]. Front Oncol , 2020 10: 556. [cited 2020 May 5] Available from: https://www.frontiersin.org/article/10.3389/fonc.2020.00556/full
16. Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA). Incidência, mortalidade e morbidade hospitalar por câncer em crianças, adolescentes e adultos jovens no Brasil: informações dos registros de câncer e do sistema de mortalidade. Rio de Janeiro, INCA, 2016
17. Ries L, Smith M, Gurney J, Linet M, Tamra T, Young J, Bunin G. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995, National Cancer Institute, SEER Program. Bethersda, MD, 1999
18. Turcotte LM, Georgieff MK, Ross JA, Feusner JH, Tomlinson GE, Malogolowkin MH, Krailo MD, Miller N, Fonstad R, Spector LG. Neonatal medical exposures and characteristics of low birth weight hepatoblastoma cases: a report from the Children’s Oncology Group. Pediatr Blood Cancer , 2014 61: 2018–2023.
19. Pateva IB, Egler RA, Stearns DS. Hepatoblastoma in an 11-year-old: Case report and a review of the literature. Medicine (Baltimore) , 2017 96: e5858.
20. Tanimura M, Matsui I, Abe J, Ikeda H, Kobayashi N, Ohira M, Yokoyama M, Kaneko M. Increased risk of hepatoblastoma among immature children with a lower birth weight. Cancer Res , 1998 58: 3032–3035.
21. DeBaun MR, Tucker MA. Risk of cancer during the first four years of life in children from The Beckwith-Wiedemann Syndrome Registry. J Pediatr , 1998 132: 398–400.
22. Kim SY, Jung S-H, Kim MS, Han M-R, Park H-C, Jung ES, Lee SH, Lee SH, Chung Y-J. Genomic profiles of a hepatoblastoma from a patient with Beckwith-Wiedemann syndrome with uniparental disomy on chromosome 11p15 and germline mutation of APC and PALB2. Oncotarget , 2017.
23. Hirschman BA, Pollock BH, Tomlinson GE. The spectrum of APC mutations in children with hepatoblastoma from familial adenomatous polyposis kindreds. J Pediatr , 2005 147: 263–266.
24. Curia MC, Zuckermann M, De Lellis L, Catalano T, Lattanzio R, Aceto G, Veschi S, Cama A, Otte J-B, Piantelli M, Mariani-Costantini R, Cetta F, Battista P. Sporadic childhood hepatoblastomas show activation of beta-catenin, mismatch repair defects and p53 mutations. Mod Pathol , 2008 21: 7–14.
25. Kamien BA, Gabbett MT. Aicardi syndrome associated with hepatoblastoma and pulmonary sequestration. Am J Med Genet A , 2009 149A: 1850–1852.
26. Pereira EM, Marion R, Ramesh KH, Kim JS, Ewart M, Ricafort R. Hepatoblastoma in a mosaic trisomy 18 patient. J Pediatr Hematol Oncol , 2012 34: e145-8.
27. Sambrook J, Russell DW. Purification of nucleic acids by extraction with phenol:chloroform. CSH Protoc , 2006 2006.
28. Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM [Internet]. 2013[cited 2020 May 18] Available from: http://github.com/lh3/bwa.
29. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, DePristo MA. The genome analysis toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res , 2010 20: 1297–1303.
30. Challis D, Yu J, Evani US, Jackson AR, Paithankar S, Coarfa C, Milosavljevic A, Gibbs RA, Yu F. An integrative variant analysis suite for whole exome next-generation sequencing data. BMC Bioinformatics , 2012 13.
31. Naslavsky MS, Scliar MO, Yamamoto GL, Wang JYT, Zverinova S, Karp T, Nunes K, Ceroni JRM, Carvalho DL de, Simões CE da S, Bozoklian D, Nonaka R, Silva N dos SB, Souza A da S, Andrade H de S, Passos MRS, Castro CFB, Mendes-Junior CT, Mercuri RL V., Miller TLA, Buzzo JL, Rego FO, Araújo NM, Magalhães WC, Mingroni-Netto RC, Borda V, Guio H, Barreto ML, Lima-Costa MF, Horta BL, Tarazona-Santos E, Meyer D, Galante PAF, Guryev V, Castelli EC, Duarte YAO, Passos-Bueno MR, Zatz M. Whole-genome sequencing of 1,171 elderly admixed individuals from the largest Latin American metropolis (São Paulo, Brazil) [Internet]. bioRxiv , 2020 10: 2020.09.15.298026. [cited 2021 Jul 7] Available from: https://www.biorxiv.org/content/10.1101/2020.09.15.298026v1
32. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, Collins RL, Laricchia KM, Ganna A, Birnbaum DP, Gauthier LD, Brand H, Solomonson M, Watts NA, Rhodes D, Singer-Berk M, England EM, Seaby EG, Kosmicki JA, Walters RK, Tashman K, Farjoun Y, Banks E, Poterba T, Wang A, Seed C, Whiffin N, Chong JX, Samocha KE, Pierce-Hoffman E, Zappala Z, O’Donnell-Luria AH, Minikel EV, Weisburd B, Lek M, Ware JS, Vittal C, Armean IM, Bergelson L, Cibulskis K, Connolly KM, Covarrubias M, Donnelly S, Ferriera S, Gabriel S, Gentry J, Gupta N, Jeandet T, Kaplan D, Llanwarne C, Munshi R, Novod S, Petrillo N, Roazen D, Ruano-Rubio V, Saltzman A, Schleicher M, Soto J, Tibbetts K, Tolonen C, Wade G, Talkowski ME, Neale BM, Daly MJ, MacArthur DG. The mutational constraint spectrum quantified from variation in 141,456 humans [Internet]. Nat 2020 5817809 , 2020 581: 434–443. [cited 2021 Jul 7] Available from: https://www.nature.com/articles/s41586-020-2308-7
33. Clarke L, Fairley S, Zheng-Bradley X, Streeter I, Perry E, Lowy E, Tassé A-M, Flicek P. The international Genome sample resource (IGSR): A worldwide collection of genome variation incorporating the 1000 Genomes Project data [Internet]. Nucleic Acids Res , 2017 45: D854–D859. [cited 2021 Jul 7] Available from: https://academic.oup.com/nar/article/45/D1/D854/2770649
34. Fuentes Fajardo K V, Adams D, Mason CE, Sincan M, Tifft C, Toro C, Boerkoel CF, Gahl W, Markello T. Detecting false-positive signals in exome sequencing. Hum Mutat , 2012 33: 609–613.
35. Stelzer G, Plaschkes I, Oz-Levi D, Alkelai A, Olender T, Zimmerman S, Twik M, Belinky F, Fishilevich S, Nudel R, Guan-Golan Y, Warshawsky D, Dahary D, Kohn A, Mazor Y, Kaplan S, Iny Stein T, Baris HN, Rappaport N, Safran M, Lancet D. VarElect: The phenotype-based variation prioritizer of the GeneCards Suite. BMC Genomics , 2016.
36. Köhler S, Carmody L, Vasilevsky N, Jacobsen JOB, Danis D, Gourdine JP, Gargano M, Harris NL, Matentzoglu N, McMurry JA, Osumi-Sutherland D, Cipriani V, Balhoff JP, Conlin T, Blau H, Baynam G, Palmer R, Gratian D, Dawkins H, Segal M, Jansen AC, Muaz A, Chang WH, Bergerson J, Laulederkind SJF, Yüksel Z, Beltran S, Freeman AF, Sergouniotis PI, Durkin D, Storm AL, Hanauer M, Brudno M, Bello SM, Sincan M, Rageth K, Wheeler MT, Oegema R, Lourghi H, Della Rocca MG, Thompson R, Castellanos F, Priest J, Cunningham-Rundles C, Hegde A, Lovering RC, Hajek C, Olry A, Notarangelo L, Similuk M, Zhang XA, Gómez-Andrés D, Lochmüller H, Dollfus H, Rosenzweig S, Marwaha S, Rath A, Sullivan K, Smith C, Milner JD, Leroux D, Boerkoel CF, Klion A, Carter MC, Groza T, Smedley D, Haendel MA, Mungall C, Robinson PN. Expansion of the Human Phenotype Ontology (HPO) knowledge base and resources. Nucleic Acids Res , 2019.
37. Kopanos C, Tsiolkas V, Kouris A, Chapple CE, Albarca Aguilera M, Meyer R, Massouras A. VarSome: the human genomic variant search engine. Bioinformatics , 2019.
38. Hampel H, Bennett RL, Buchanan A, Pearlman R, Wiesner GL, Guideline Development Group, American College of Medical Genetics and Genomics Professional Practice and Guidelines Committee and National Society of Genetic Counselors Practice Guidelines Committee. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. [Internet]. Genet Med , 2015 17: 70–87. [cited 2019 Aug 4] Available from: http://www.ncbi.nlm.nih.gov/pubmed/25394175
39. LSue Richards, PhD1 , Nazneen Aziz, PhD2, 16 , Sherri Bale, PhD3 , David Bick M, , Soma Das P, Julie Gastier-Foster, PhD6, 7, 8, Wayne W. Grody, MD, PhD9, 10, 11, Madhuri Hegde P, Elaine Lyon P, , Elaine Spector P, , Karl Voelkerding M, and Heidi L. Rehm P, On ;, Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL, Laboratories KD, Genetics M, Health O, Road P, Molecular C, Children N, State O, Berindan-neagoe I, Monroig P, Pasculli B, George A, Medicine T, Hatieganu PI, Juan S, Rico P, Sciences P, Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology Sue. Genet Med , 2015.
40. Oscanoa J, Sivapalan L, Gadaleta E, Dayem Ullah AZ, Lemoine NR, Chelala C. SNPnexus: a web server for functional annotation of human genome sequence variation (2020 update). Nucleic Acids Res , 2020 48: W185–W192.
41. Oliveira D, Leal GF, Sertie AL, Caires LCJ, Goulart E, Musso CM, Oliveira JRM de, Krepischi ACV, Vianna-Morgante AM, Zatz M. 10q23.31 microduplication encompassing PTEN decreases mTOR signalling activity and is associated with autosomal dominant primary microcephaly. J Med Genet , 2018.
42. Spector LG, Birch J. The epidemiology of hepatoblastoma. Pediatr Blood Cancer , 2012.
43. Czauderna P, Haeberle B, Hiyama E, Rangaswami A, Krailo M, Maibach R, Rinaldi E, Feng Y, Aronson D, Malogolowkin M, Yoshimura K, Leuschner I, Lopez-Terrada D, Hishiki T, Perilongo G, von Schweinitz D, Schmid I, Watanabe K, Derosa M, Meyers R. The Children’s Hepatic tumors International Collaboration (CHIC): Novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model. Eur J Cancer , 2016 52: 92–101.
44. Meyers RL, Maibach R, Hiyama E, Haberle B, Krailo M, Rangaswami A, Aronson DC, Malogolowkin MH, Perilongo G, von Schweinitz D, Ansari M, Lopez-Terrada D, Tanaka Y, Alaggio R, Leuschner I, Hishiki T, Schmid I, Watanabe K, Yoshimura K, Feng Y, Rinaldi E, Saraceno D, Derosa M, Czauderna P. Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children’s Hepatic tumors International Collaboration. Lancet Oncol , 2017 18: 122–131.
45. Pinto RB, Ramos ARL, Backes AN, Santos BJ Dos, Provenzi VO, Carbonera MR, Roenick ML, Santos PPA Dos, Falhauber F, Souza MV de, Bassols JV, Artigalas O. Hirschsprung disease and hepatoblastoma: case report of a rare association. Sao Paulo Med J , 2016 134: 171–175.
46. Rahman N. Realizing the promise of cancer predisposition genes. Nature , 2014 505: 302–308.
47. Foulkes WD, Priest JR, Duchaine TF. DICER1: mutations, microRNAs and mechanisms. Nat Rev Cancer , 2014 14: 662–672.
48. Johnson KJ, Lee JM, Ahsan K, Padda H, Feng Q, Partap S, Fowler SA, Druley TE. Pediatric cancer risk in association with birth defects: A systematic review. PLoS One , 2017 12: e0181246.
49. Krivit W, Good RA. Simultaneous Occurrence of Mongolism and Leukemia: Report of a Nationwide Survey. AMA J Dis Child , 1957.
50. Agha MM, Williams JI, Marrett L, To T, Zipursky A, Dodds L. Congenital abnormalities and childhood cancer. Cancer , 2005 103: 1939–1948.
51. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin , 2017 67: 7–30.
52. Norwood MS, Lupo PJ, Chow EJ, Scheurer ME, Plon SE, Danysh HE, Spector LG, Carozza SE, Doody DR, Mueller BA. Childhood cancer risk in those with chromosomal and non-chromosomal congenital anomalies in Washington State: 1984-2013. PLoS One , 2017 12: e0179006.
53. Scollon S, Anglin AK, Thomas M, Turner JT, Wolfe Schneider K. A Comprehensive Review of Pediatric Tumors and Associated Cancer Predisposition Syndromes. J Genet Couns , 2017 26: 387–434.
54. Ansell P, Mitchell CD, Roman E, Simpson J, Birch JM, Eden TOB. Relationships between perinatal and maternal characteristics and hepatoblastoma: a report from the UKCCS. Eur J Cancer , 2005 41: 741–748.
55. Narod SA, Hawkins MM, Robertson CM, Stiller CA. Congenital anomalies and childhood cancer in Great Britain. Am J Hum Genet , 1997 60: 474–485.
56. de Camargo B, de Oliveira Ferreira JM, de Souza Reis R, Ferman S, de Oliveira Santos M, Pombo-de-Oliveira MS. Socioeconomic status and the incidence of non-central nervous system childhood embryonic tumours in Brazil. BMC Cancer , 2011.
57. Venkatramani R, Spector LG, Georgieff M, Tomlinson G, Krailo M, Malogolowkin M, Kohlmann W, Curtin K, Fonstad RK, Schiffman JD. Congenital abnormalities and hepatoblastoma: a report from the Children’s Oncology Group (COG) and the Utah Population Database (UPDB). Am J Med Genet A , 2014 164A: 2250–2255.
58. Sergi CM, Caluseriu O, McColl H, Eisenstat DD. Hirschsprung’s disease: clinical dysmorphology, genes, micro-RNAs, and future perspectives. Pediatr Res , 2017 81: 177–191.
59. Heuckeroth RO. Hirschsprung disease - integrating basic science and clinical medicine to improve outcomes. Nat Rev Gastroenterol Hepatol , 2018 15: 152–167.
60. Williams LA, Spector LG. Survival Differences Between Males and Females Diagnosed With Childhood Cancer. JNCI cancer Spectr , 2019 3: pkz032.
61. Krepischi ACV, Pearson PL, Rosenberg C. Germline copy number variations and cancer predisposition. Future Oncol , 2012 8: 441–450.
62. Lalatta F, Folliero E, Cavallari U, Segni M Di, Gentilin B, Fogliani R, Quagliarini D, Vizziello P, Monti F, Gargantini L. Early manifestations in a cohort of children prenatally diagnosed with 47,XYY. Role of multidisciplinary counseling for parental guidance and prevention of aggressive behavior [Internet]. Ital J Pediatr , 2012 38: 52. [cited 2021 Aug 18] Available from: /pmc/articles/PMC3523010/
63. Bardsley MZ, Kowal K, Levy C, Gosek A, Ayari N, Tartaglia N, Lahlou N, Winder B, Grimes S, Ross JL. 47,XYY Syndrome: Clinical Phenotype and Timing of Ascertainment [Internet]. J Pediatr , 2013 163: 1085. [cited 2021 Sep 28] Available from: /pmc/articles/PMC4097881/
64. Butler MG. Clinical and genetic aspects of the 15q11.2 BP1-BP2 microdeletion disorder. J Intellect Disabil Res , 2017 61: 568–579.
65. Rafi SK, Butler MG. The 15q11.2 BP1-BP2 Microdeletion (Burnside-Butler) Syndrome: In Silico Analyses of the Four Coding Genes Reveal Functional Associations with Neurodevelopmental Phenotypes. Int J Mol Sci , 2020 21.
66. Ma X, Liu Y, Liu Y, Alexandrov LB, Edmonson MN, Gawad C, Zhou X, Li Y, Rusch MC, John E, Huether R, Gonzalez-Pena V, Wilkinson MR, Hermida LC, Davis S, Sioson E, Pounds S, Cao X, Ries RE, Wang Z, Chen X, Dong L, Diskin SJ, Smith MA, Auvi JMG, Meltzer PS, Lau CC, Perlman EJ, Maris JM, Meshinchi S, Hunger SP, Gerhard DS, Zhang J. Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. Nature , 2018 555: 371–376.
67. Fitzky BU, Witsch-Baumgartner M, Erdel M, Lee JN, Paik Y-K, Glossmann H, Utermann G, Moebius FF. Mutations in the Δ7-sterol reductase gene in patients with the Smith–Lemli–Opitz syndrome [Internet]. Proc Natl Acad Sci , 1998 95: 8181–8186. [cited 2021 Jul 7] Available from: https://www.pnas.org/content/95/14/8181
68. Shahi RB, De Brakeleer S, Caljon B, Pauwels I, Bonduelle M, Joris S, Fontaine C, Vanhoeij M, Van Dooren S, Teugels E, De Grève J. Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families. BMC Cancer , 2019 19: 313.
69. Rahman N, Scott RH. Cancer genes associated with phenotypes in monoallelic and biallelic mutation carriers: New lessons from old players. Hum Mol Genet , 2007.
70. Savary C, Kim A, Lespagnol A, Gandemer V, Pellier I, Andrieu C, Pagès G, Galibert MD, Blum Y, de Tayrac M. Depicting the genetic architecture of pediatric cancers through an integrative gene network approach. Sci Rep , 2020 10: 1–15.
71. Thompson D, Duedal S, Kirner J, McGuffog L, Last J, Reiman A, Byrd P, Taylor M, Easton DF. Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst , 2005 97: 813–822.
72. Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, Ahmed M, North B, Jayatilake H, Barfoot R, Spanova K, McGuffog L, Evans DG, Eccles D, Easton DF, Stratton MR, Rahman N. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet , 2006 38: 873–875.
73. Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylkas K, Roberts J, Lee A, Subramanian D, De Leeneer K, Fostira F, Tomiak E, Neuhausen SL, Teo ZL, Khan S, Aittomaki K, Moilanen JS, Turnbull C, Seal S, Mannermaa A, Kallioniemi A, Lindeman GJ, Buys SS, Andrulis IL, Radice P, Tondini C, Manoukian S, Toland AE, Miron P, Weitzel JN, Domchek SM, Poppe B, Claes KBM, Yannoukakos D, Concannon P, Bernstein JL, James PA, Easton DF, Goldgar DE, Hopper JL, Rahman N, Peterlongo P, Nevanlinna H, King M-C, Couch FJ, Southey MC, Winqvist R, Foulkes WD, Tischkowitz M. Breast-cancer risk in families with mutations in PALB2. N Engl J Med , 2014 371: 497–506.
74. Helgason H, Rafnar T, Olafsdottir HS, Jonasson JG, Sigurdsson A, Stacey SN, Jonasdottir A, Tryggvadottir L, Alexiusdottir K, Haraldsson A, le Roux L, Gudmundsson J, Johannsdottir H, Oddsson A, Gylfason A, Magnusson OT, Masson G, Jonsson T, Skuladottir H, Gudbjartsson DF, Thorsteinsdottir U, Sulem P, Stefansson K. Loss-of-function variants in ATM confer risk of gastric cancer [Internet]. Nat Genet , 2015 47: 906–910. [cited 2020 Feb 29] Available from: http://www.nature.com/articles/ng.3342
75. Esteban-Jurado C, Franch-Expósito S, Muñoz J, Ocaña T, Carballal S, López-Cerón M, Cuatrecasas M, Vila-Casadesús M, Lozano JJ, Serra E, Beltran S, Brea-Fernández A, Ruiz-Ponte C, Castells A, Bujanda L, Garre P, Caldés T, Cubiella J, Balaguer F, Castellví-Bel S. The Fanconi anemia DNA damage repair pathway in the spotlight for germline predisposition to colorectal cancer [Internet]. Eur J Hum Genet , 2016 24: 1501–1505. [cited 2020 Feb 29] Available from: http://www.nature.com/articles/ejhg201644
76. Esai Selvan M, Klein RJ, Gümüş ZH. Rare, Pathogenic Germline Variants in Fanconi Anemia Genes Increase Risk for Squamous Lung Cancer [Internet]. Clin Cancer Res , 2019 25: 1517–1525. [cited 2020 Feb 29] Available from: http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-18-2660
77. Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, Mazoyer S, Chenevix-Trench G, Easton DF, Antoniou AC, Nathanson KL, Laitman Y, Kushnir A, Paluch-Shimon S, Berger R, Zidan J, Friedman E, Ehrencrona H, Stenmark-Askmalm M, Einbeigi Z, Loman N, Harbst K, Rantala J, Melin B, Huo D, Olopade OI, Seldon J, Ganz PA, Nussbaum RL, Chan SB, Odunsi K, Gayther SA, Domchek SM, Arun BK, Lu KH, Mitchell G, Karlan BY, Walsh C, Lester J, Godwin AK, Pathak H, Ross E, Daly MB, Whittemore AS, John EM, Miron A, Terry MB, Chung WK, Goldgar DE, Buys SS, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg EJ, Steele L, Neuhausen SL, Ding YC, Ejlertsen B, Gerdes A-M, Hansen T v O, Ramon y Cajal T, Osorio A, Benitez J, Godino J, Tejada M-I, Duran M, Weitzel JN, Bobolis KA, Sand SR, Fontaine A, Savarese A, Pasini B, Peissel B, Bonanni B, Zaffaroni D, Vignolo-Lutati F, Scuvera G, Giannini G, Bernard L, Genuardi M, Radice P, Dolcetti R, Manoukian S, Pensotti V, Gismondi V, Yannoukakos D, Fostira F, Garber J, Torres D, Rashid MU, Hamann U, Peock S, Frost D, Platte R, Evans DG, Eeles R, Davidson R, Eccles D, et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA , 2015 313: 1347–1361.
78. Swift M, Zimmerman D, McDonough ER. Squamous cell carcinomas in Fanconi’s anemia. JAMA , 1971 216: 325–326.
79. Suter M, Abramovici A, Showalter L, Hu M, Shope C Do, Varner M, Aagaard-Tillery K. IN UTERO TOBACCO EXPOSURE EPIGENETICALLY MODIFIES PLACENTAL CYP1A1 EXPRESSION [Internet]. Metabolism , 2010 59: 1481. [cited 2021 Jul 7] Available from: /pmc/articles/PMC2921565/
80. Yan Y, Wang H, Feng Y. Alterations of placental cytochrome P450 1A1 and P-glycoprotein in tobacco-induced intrauterine growth retardation in rats [Internet]. Acta Pharmacol Sin 2005 2611 , 2005 26: 1387–1394. [cited 2021 Jul 7] Available from: https://www.nature.com/articles/aps2005203
81. Stejskalova L, Pavek P. The function of cytochrome P450 1A1 enzyme (CYP1A1) and aryl hydrocarbon receptor (AhR) in the placenta. Curr Pharm Biotechnol , 2011 12: 715–730.
82. Kapelyukh Y, Henderson CJ, Scheer N, Rode A, Wolf CR. Defining the Contribution of CYP1A1 and CYP1A2 to Drug Metabolism Using Humanized CYP1A1/1A2 and Cyp1a1/Cyp1a2 Knockout Mice [Internet]. Drug Metab Dispos , 2019 47: 907. [cited 2021 Jul 7] Available from: /pmc/articles/PMC6657216/
83. Willis AJ, Indra R, Wohak LE, Sozeri O, Feser K, Mrizova I, Phillips DH, Stiborova M, Arlt VM. The impact of chemotherapeutic drugs on the CYP1A1-catalysed metabolism of the environmental carcinogen benzo[a]pyrene: Effects in human colorectal HCT116 TP53(+/+), TP53(+/−) and TP53(−/−) cells. Toxicology , 2018 398–399: 1–12.
84. Ito S, Chen C, Satoh J, Yim S, Gonzalez FJ. Dietary phytochemicals regulate whole-body CYP1A1 expression through an arylhydrocarbon receptor nuclear translocator–dependent system in gut [Internet]. J Clin Invest , 2007 117: 1940. [cited 2021 Jul 7] Available from: /pmc/articles/PMC1890999/
85. Delescluse C, Lemaire G, de Sousa G, Rahmani R. Is CYP1A1 induction always related to AHR signaling pathway? [Internet]. Toxicology , 2000 153: 73–82. [cited 2020 Mar 31] Available from: http://www.ncbi.nlm.nih.gov/pubmed/11090948
86. Kawashiro T, Yamashita K, Zhao XJ, Koyama E, Tani M, Chiba AN, Ishizaki T. A study on the metabolism of etoposide and possible interactions with antitumor or supporting Agents by Human Liver Microsomes. J Pharmacol Exp Ther , 1998 286: 1294–1300.
87. Kamenickova A, Anzenbacherova E, Pavek P, Soshilov AA, Denison MS, Zapletalova M, Anzenbacher P, Dvorak Z. Effects of anthocyanins on the AhR-CYP1A1 signaling pathway in human hepatocytes and human cancer cell lines [Internet]. Toxicol Lett , 2013 221: 1. [cited 2021 Sep 28] Available from: /pmc/articles/PMC3759295/
88. Shahin NN, Abd-Elwahab GT, Tawfiq AA, Abdelgawad HM. Potential role of aryl hydrocarbon receptor signaling in childhood obesity. Biochim Biophys Acta - Mol Cell Biol Lipids , 2020 1865: 158714.
89. Schanz O, Chijiiwa R, Cengiz SC, Majlesain Y, Weighardt H, Takeyama H, Förster I. Dietary AhR Ligands Regulate AhRR Expression in Intestinal Immune Cells and Intestinal Microbiota Composition [Internet]. Int J Mol Sci , 2020 21. [cited 2021 Jul 7] Available from: /pmc/articles/PMC7246938/
90. Lu J, Shang X, Zhong W, Xu Y, Shi R, Wang X. New insights of CYP1A in endogenous metabolism: a focus on single nucleotide polymorphisms and diseases. Acta Pharm Sin B , 2020 10: 91–104.
91. Larigot L, Juricek L, Dairou J, Coumoul X. AhR signaling pathways and regulatory functions. Biochim Open , 2018 7: 1–9.
92. Stejskalova L, Dvorak Z, Pavek P. Endogenous and Exogenous Ligands of Aryl Hydrocarbon Receptor: Current State of Art. 2011
93. Alexandrov LB, Jones PH, Wedge DC, Sale JE, Campbell PJ, Nik-Zainal S, Stratton MR. Clock-like mutational processes in human somatic cells. Nat Genet , 2015 47: 1402–1407.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.